{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:20:03Z","timestamp":1788240003301,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.7759\/cureus.115561","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:05:25Z","timestamp":1788239125000},"source":"Crossref","is-referenced-by-count":0,"title":["Transition Toward Multimodal Integration in Cancer Therapy: Biological Rationales, Clinical Efficacy, and Pharmacological Challenges"],"prefix":"10.7759","author":[{"given":"Khwairakpam Devendra","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack I","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018, 15:81-94. 10.1038\/nrclinonc.2017.166","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan N","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019, 575:299-309. 10.1038\/s41586-019-1730-1","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan D","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022, 12:31-46. 10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.02.003","article-title":"Polytherapy and targeted cancer drug resistance","volume":"5","author":"Chatterjee N","year":"2019","unstructured":"Chatterjee N, Bivona TG. Polytherapy and targeted cancer drug resistance. Trends Cancer. 2019, 5:170-82. 10.1016\/j.trecan.2019.02.003","journal-title":"Trends Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1390263","article-title":"Emerging role of immunogenic cell death in cancer immunotherapy","volume":"15","author":"Arimoto KI","year":"2024","unstructured":"Arimoto KI, Miyauchi S, Liu M, Zhang DE. Emerging role of immunogenic cell death in cancer immunotherapy. Front Immunol. 2024, 15:1390263. 10.3389\/fimmu.2024.1390263","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu B","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KT, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024, 9:175. 10.1038\/s41392-024-01856-7","journal-title":"Signal Transduct Target Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00568-1","article-title":"Immunomodulation by radiotherapy in tumour control and normal tissue toxicity","volume":"22","author":"Cytlak UM","year":"2022","unstructured":"Cytlak UM, Dyer DP, Honeychurch J, Williams KJ, Travis MA, Illidge TM. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat Rev Immunol. 2022, 22:124-38. 10.1038\/s41577-021-00568-1","journal-title":"Nat Rev Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology","volume":"25","author":"Sabnis AJ","year":"2019","unstructured":"Sabnis AJ, Bivona TG. Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology. Trends Mol Med. 2019, 25:185-97. 10.1016\/j.molmed.2018.12.009","journal-title":"Trends Mol Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454720","article-title":"Companion diagnostics and predictive biomarkers for PD-1\/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma","volume":"15","author":"Wang Z","year":"2024","unstructured":"Wang Z, Zou X, Wang H, Hao Z, Li G, Wang S. Companion diagnostics and predictive biomarkers for PD-1\/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma. Front Immunol. 2024, 15:1454720. 10.3389\/fimmu.2024.1454720","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda SM","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024, 21:47-66. 10.1038\/s41571-023-00832-4","journal-title":"Nat Rev Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.12.009","article-title":"Artificial intelligence-based multi-omics analysis fuels cancer precision medicine","volume":"88","author":"He X","year":"2023","unstructured":"He X, Liu X, Zuo F, Shi H, Jing J. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Semin Cancer Biol. 2023, 88:187-200. 10.1016\/j.semcancer.2022.12.009","journal-title":"Semin Cancer Biol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06139-5","article-title":"The clinical application of artificial intelligence in cancer precision treatment","volume":"23","author":"Wang J","year":"2025","unstructured":"Wang J, Zeng Z, Li Z, et al.. The clinical application of artificial intelligence in cancer precision treatment. J Transl Med. 2025, 23:120. 10.1186\/s12967-025-06139-5","journal-title":"J Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the Rosetta Stone of therapy resistance","volume":"37","author":"Marusyk A","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell. 2020, 37:471-84. 10.1016\/j.ccell.2020.03.007","journal-title":"Cancer Cell"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine JC","year":"2020","unstructured":"Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020, 20:743-56. 10.1038\/s41568-020-00302-4","journal-title":"Nat Rev Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi S","year":"2020","unstructured":"Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020, 19:39-56. 10.1038\/s41573-019-0044-1","journal-title":"Nat Rev Drug Discov"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00660-9","article-title":"Beyond genetics: driving cancer with the tumour microenvironment behind the wheel","volume":"24","author":"Yuan S","year":"2024","unstructured":"Yuan S, Almagro J, Fuchs E. Beyond genetics: driving cancer with the tumour microenvironment behind the wheel. Nat Rev Cancer. 2024, 24:274-86. 10.1038\/s41568-023-00660-9","journal-title":"Nat Rev Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.124.000951","article-title":"Drug-drug interactions and synergy: from pharmacological models to clinical application","volume":"76","author":"Calzetta L","year":"2024","unstructured":"Calzetta L, Page C, Matera MG, Cazzola M, Rogliani P. Drug-drug interactions and synergy: from pharmacological models to clinical application. Pharmacol Rev. 2024, 76:1159-220. 10.1124\/pharmrev.124.000951","journal-title":"Pharmacol Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational cancer treatment combinations: an urgent clinical need","volume":"78","author":"Boshuizen J","year":"2020","unstructured":"Boshuizen J, Peeper DS. Rational cancer treatment combinations: an urgent clinical need. Mol Cell. 2020, 78:1002-18. 10.1016\/j.molcel.2020.05.031","journal-title":"Mol Cell"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00758-4","article-title":"A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov","volume":"14","author":"Yang J","year":"2023","unstructured":"Yang J, Kang H, Lyu L, Xiong W, Hu Y. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov. Discov Oncol. 2023, 14:151. 10.1007\/s12672-023-00758-4","journal-title":"Discov Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura D","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018, 15:325-40. 10.1038\/nrclinonc.2018.29","journal-title":"Nat Rev Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi L","year":"2020","unstructured":"Galluzzi L, Vitale I, Warren S, et al.. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020, 8:10.1136\/jitc-2019-000337","journal-title":"J Immunother Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield LH","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024, 24:399-416. 10.1038\/s41577-023-00973-8","journal-title":"Nat Rev Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee H","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, et al.. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023, 389:491-503. 10.1056\/NEJMoa2302983","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring LM","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al.. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020, 26:2838-48. 10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.003","article-title":"Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer","volume":"31","author":"De Ruysscher D","year":"2020","unstructured":"De Ruysscher D, Faivre-Finn C, Nackaerts K, et al.. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Ann Oncol. 2020, 31:41-9. 10.1016\/j.annonc.2019.10.003","journal-title":"Ann Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy T","year":"2021","unstructured":"Conroy T, Bosset J-F, Etienne P-L, et al.. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22:702-15. 10.1016\/S1470-2045(21)00079-6","journal-title":"Lancet Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00085","article-title":"The multidisciplinary team (MDT) approach and quality of care","volume":"10","author":"Taberna M","year":"2020","unstructured":"Taberna M, Gil Moncayo F, Jan\u00e9-Salas E, et al.. The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020, 10:85. 10.3389\/fonc.2020.00085","journal-title":"Front Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld AJ","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020, 37:443-55. 10.1016\/j.ccell.2020.03.017","journal-title":"Cancer Cell"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles T","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, et al.. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024, 390:875-88. 10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00185","article-title":"Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions","volume":"9","author":"Wang Y","year":"2018","unstructured":"Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol. 2018, 9:185. 10.3389\/fphar.2018.00185","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield K","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, et al.. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021, 184:596-614.e14. 10.1016\/j.cell.2021.01.002","journal-title":"Cell"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF-MEK pathway","volume":"9","author":"Yaeger R","year":"2019","unstructured":"Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019, 9:329-41. 10.1158\/2159-8290.CD-18-1321","journal-title":"Cancer Discov"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou AM","year":"2020","unstructured":"Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020, 86:102019. 10.1016\/j.ctrv.2020.102019","journal-title":"Cancer Treat Rev"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard I","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al.. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019, 381:2416-28. 10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini BI","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, et al.. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019, 380:1116-27. 10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon DW","year":"2020","unstructured":"Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020, 1:276-90. 10.1038\/s43018-020-0043-5","journal-title":"Nat Cancer"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June CH","year":"2018","unstructured":"June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018, 359:1361-5. 10.1126\/science.aar6711","journal-title":"Science"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan MW","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, et al.. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022, 387:2113-25. 10.1056\/NEJMoa2210233","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet JM","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021, 18:293-313. 10.1038\/s41575-020-00395-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai K","year":"2024","unstructured":"Ai K, Liu B, Chen X, et al.. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024, 17:105. 10.1186\/s13045-024-01625-7","journal-title":"J Hematol Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq S","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020, 17:147-67. 10.1038\/s41571-019-0297-y","journal-title":"Nat Rev Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2019.1623429","article-title":"Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality","volume":"95","author":"Ko EC","year":"2019","unstructured":"Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019, 95:936-9. 10.1080\/09553002.2019.1623429","journal-title":"Int J Radiat Biol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde LA","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, et al.. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021, 39:1485-505. 10.1200\/JCO.20.03399","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.5041","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): updated analysis of the adaptive abiraterone (abi) study (NCT02415621)","volume":"37","author":"Zhang J","year":"2019","unstructured":"Zhang J, Fishman MN, Brown J, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): updated analysis of the adaptive abiraterone (abi) study (NCT02415621). J Clin Oncol. 2019, 37:5041. 10.1200\/JCO.2019.37.15_suppl.5041","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1941","article-title":"Eradicating metastatic cancer and the eco-evolutionary dynamics of anthropocene extinctions","volume":"80","author":"Gatenby RA","year":"2020","unstructured":"Gatenby RA, Artzy-Randrup Y, Epstein T, Reed DR, Brown JS. Eradicating metastatic cancer and the eco-evolutionary dynamics of anthropocene extinctions. Cancer Res. 2020, 80:613-23. 10.1158\/0008-5472.CAN-19-1941","journal-title":"Cancer Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie J","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, et al.. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022, 386:2261-72. 10.1056\/NEJMoa2200075","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang X","year":"2024","unstructured":"Wang X, Lamberti G, Di Federico A, et al.. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann Oncol. 2024, 35:508-22. 10.1016\/j.annonc.2024.03.007","journal-title":"Ann Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma L","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, et al.. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024, 9:336. 10.1038\/s41392-024-02021-w","journal-title":"Signal Transduct Target Ther"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01003-3","article-title":"Emerging clinical applications of single-cell RNA sequencing in oncology","volume":"22","author":"Boxer E","year":"2025","unstructured":"Boxer E, Feigin N, Tschernichovsky R, et al.. Emerging clinical applications of single-cell RNA sequencing in oncology. Nat Rev Clin Oncol. 2025, 22:315-26. 10.1038\/s41571-025-01003-3","journal-title":"Nat Rev Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00694-7","article-title":"A guide to artificial intelligence for cancer researchers","volume":"24","author":"Perez-Lopez R","year":"2024","unstructured":"Perez-Lopez R, Ghaffari Laleh N, Mahmood F, Kather JN. A guide to artificial intelligence for cancer researchers. Nat Rev Cancer. 2024, 24:427-41. 10.1038\/s41568-024-00694-7","journal-title":"Nat Rev Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/520770-transition-toward-multimodal-integration-in-cancer-therapy-biological-rationales-clinical-efficacy-and-pharmacological-challenges","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:05:26Z","timestamp":1788239126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/520770-transition-toward-multimodal-integration-in-cancer-therapy-biological-rationales-clinical-efficacy-and-pharmacological-challenges"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.115561","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}